Reduced noradrenaline levels have been reported to occur in the motor cortices of PD patients postmortem.
Parkinson's disease (PD) is a neurodegenerative disorder affecting several major neurotransmitter systems. In particular, postmortem studies have reported considerable degeneration of the locus coeruleus (LC), which supplies the cortex with noradrenaline. 1 Postmortem, multiple brain regions were reported to exhibit reduced levels of noradrenaline, including the cerebellar cortex, thalamus, and cerebral cortex including the motor cortex. [2] [3] [4] [5] With in vivo imaging using positron emission tomography (PET) with 18 Fdopa, which is taken up and decarboxylated by monoaminergic terminals, including dopaminergic, serotonergic and noradrenergic neurons, Moore and colleagues showed decreased signal, specifically in the motor cortex. 6 Newer PET ligands based on a reboxetine structure, such as 11 C-MeNER, provide a specific marker of noradrenaline transporter function, 7, 8 and a recently proposed MeNER PET analysis approach allowed in vivo estimation of cortical noradrenaline transporter availability in healthy subjects. 9 The objective of this 11 C-MeNER PET study was to examine the hypothesis that noradrenaline transporter function is decreased in cortical regions of PD patients compared with matched healthy control (HC) subjects.
Methods Study Design and Participants
We recruited 30 PD patients for imaging with 11 CMeNER PET. Inclusion criteria were diagnosis of PD according to the Movement Disorder Society (MDS) consensus criteria, 10 aged 50-85 years, a geriatric depression scale (GDS-15) score < 6, and Montreal cognitive assessment (MoCA) score > 22. Exclusion criteria were a diagnosis of dementia, medication acting on the noradrenergic transporter, and significant white-matter lesions. Total levodopa-equivalent daily doses were calculated as previously recommended.
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Olfaction was tested with the 16-item Sniffin' Sticks battery. Motor symptoms were quantified using the MDS Unified PD Rating Scale part III (MDS-UPDRS 12 PD patients were compared with 12 age-and sex-matched cognitively normal (MoCA > 26) and nondepressed (GDS-15 < 6) HC subjects without a history of neurological disorders and with a normal brain MRI (Table  1) . A volume-of-interest analysis of noradrenaline transporter (NAT) density in subcortical structures of the 42 subjects was previously reported. 12 The study was approved by the local ethical committee. All subjects gave written informed consent according to the Declaration of Helsinki.
C-MeNER PET
Details of 11 C-MeNER radiosynthesis and image reconstruction and normalization are provided as supplementary material. A 4-mm Gaussian filter was applied to the normalized images before calculation of parametric maps of binding potentials nondisplaceable (BP ND ) using the simplified reference tissue model 2. Voxel-wise calculations in PXMOD were initiated with time-activity curves of the thalamus as a highbinding region and the caudate as a low-binding region; the efflux constant of the reference region was fixed at k2 0 5 0.021 min -1 , as previously published. 7, 9 BP ND values of the left 1 right precentral and postcentral gyri were extracted for group comparisons.
MRI
An MPRAGE sequence was acquired on a Siemens Magnetom Tim Trio scanner using a 32-channel head coil and the following parameters: TR/TI/TE, 960/ 2420/3.7 milliseconds; flip angle, 9 degrees; number of slices, 176; FOV 256 3 256 mm; 1-mm isotropic resolution; and an iPAT factor of 2 using grappa. Cortical gray-matter thickness was estimated using the standard presets in FreeSurfer 5.3 (http://surfer.nmr.mgh. harvard.edu/).
Statistical Parametric Mapping
All individual parametric maps were nonrigidly transformed to an 11 C-MeNER spatial template derived from an averaged image of the 12 HC subjects, and Statistical Parametric Mapping 12 (SPM12) in Matlab2015b was used for between-group comparisons of 11 C-MeNER binding potentials at a voxel level (2-sample t test between PD patients and HC subjects). Parametric maps were smoothed with a 4-mm Gaussian filter, and an average cortical gray-matter mask was used for explicit masking within the SPM software. The voxel-level analysis threshold was P < 0.005 (uncorrected), and subsequently a familywise error cluster-level correction at P < 0.05 was applied. Surface projections of the resulting voxels were overlaid on a rendered brain of an HC subject.
Statistical Analysis
We analyzed the data with Statistical Package for the Social Sciences (SPSS) version 24. Group data were presented as mean 6 standard deviation. Group comparisons were interrogated with the Student t, Mann-Whitney, and chi-square statistics as appropriate; a normal distribution of data was assessed with the Shapiro-Wilk test. Volume-of-interest (VOI) analysis of BP ND values was tested with a repeatedmeasures analysis of variance (ANOVA). Significance was accepted at P < 0.05.
Results
Demographic and clinical characteristics of PD patients and HC subjects are summarized in Table 1 . Groups did not differ with regard to age, sex, and MoCA score. In the voxel-wise comparison, PD patients showed lower cortical 11 C-MeNER binding tracking the primary motor cortex and, to a lesser extent, the primary sensory cortex (Fig. 1A) . Similarly, VOI analysis of the precentral and postcentral gyri showed significant reduced (Fig. 1B) . However, a direct comparison of mild and more severely affected PD groups revealed no significant NAT cortical-binding differences.
C O R T I C A L N O R A D R E N A L I N E T R A N S P O R T E R

Discussion
Previous
11
C-MeNER studies on PD patients from our group analyzed subcortical high-binding areas of MeNER, revealing reduced 11 C-MeNER binding in the thalamus and hypothalamus as well as the brain stem nuclei. 8, 12 Using the recently proposed imaging analysis approach for cortical MeNER uptake from Moriguchi and colleagues, 9 we report here the first in vivo evidence of impaired noradrenergic function in the primary motor cortex in PD patients using a specific PET ligand for noradrenergic transporter binding. In addition, we were able to show that patients with more advanced disease have a pronounced decline in 11 C-MeNER availability in the primary motor cortex. Growing evidence suggests involvement of multiple neurotransmitters in PD and, in line with the results from the present study, point to significant dysfunction of the noradrenergic system associated with more severe motor disability in PD. 4, 13, 14 The LC is affected by a-synuclein aggregates in Braak stage 2 of PD during its trajectory, which precedes and may even surpass later involvement of the substantia nigra. 15, 16 Evidence from animal studies has implicated noradrenergic dysfunction in the appearance and aggravation of motor symptoms. Several studies showed that deficient noradrenergic innervation amplified dopaminergic cell loss in toxin-derived PD models. [17] [18] [19] In mice with MPTP-induced dopaminergic lesions, the PD-like motor phenotype is only manifested when there is noradrenergic codeficiency. 20 Noradrenaline deficits also attenuated beneficial levodopa replacement effects on motor symptoms in rats lesioned with 6-hydroxydopamine.
14 In addition, amphetamines could restore locomotor activity in a dopamine-independent way in a novel PD mouse model. 21 Data on manipulation of the noradrenergic system to improve motor function in human PD is scarce. One small-scale open-label study trialed duloxetine, a combined serotonin and noradrenaline reuptake inhibitor and reported beneficial effects on motor symptoms in PD. 22 Of note, paroxetine, which is a selective serotonin reuptake inhibitor, did not improve motor symptoms. 23 Methylphenidate, which is a dual dopamine and noradrenaline reuptake inhibitor, showed beneficial effects on motor symptoms in PD; however, its effects became insignificant with coadministration of high doses of 
levodopa. 24, 25 The noradrenergic prodrug droxidopa is approved for orthostatic hypotension in PD and was reported to improve UPDRS III scores in 1 study. 26 PD is pathologically characterized not only by perturbed function of the substantia nigra and basal ganglia circuitry, but also of cortical networks, including dysfunction of primary motor cortex connections. [27] [28] [29] [30] Neural plasticity of the primary motor cortex is altered in PD, 31 and facilitation of its excitability by transcranial direct current stimulation has been shown to improve motor performance in PD patients. 32 Concordantly, abnormal suppression of electroencephalographic activity during a motor task was observed in PD patients. 33 Using 18 F-dopa PET, Moore and colleagues reported that the primary motor cortex exhibited a monoaminergic deficit in early PD, which then spread anteriorly and laterally with disease progression. 6 A cortical deficit of the noradrenergic system has also been reported in a postmortem study. 2 Our in vivo results confirm a noradrenergic influence on motor symptoms and altered functioning of the primary motor cortex in PD.
Several limitations of our study have to be mentioned. Cortical-binding potentials of 11 C-MeNER tend to be low, impeding statistical power. 9 However, we recruited a relatively robust number of subjects, 42, for PET and employed corrected SPM analyses as well as VOI-based statistics. As specific binding was very low in the cortices of PD patients, we also minimized subgroup analysis to avoid low statistical power. Larger sample sizes and future noradrenergic PET ligands with higher signal-to-noise properties might be able to detect more subtle deficits in PD and might facilitate analysis of specific PD subgroups and their association with cortical noradrenergic innervation. These studies should also address the laterality of PD symptoms and their correlation with cortical noradrenergic innervation. We also did not assess potential reductions of other monoamines. Future studies using multitracer approaches are needed for quantifying and comparing deficits of specific monoamines in the motor cortex of those with PD. 6 In conclusion, this study provides in vivo evidence for altered noradrenergic transmission in the motor cortices in PD patients, which is associated with greater disease severity. Thus, our results suggest that noradrenergic dysfunction may contribute to motor deterioration in PD.
